KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Work In Process: 2009-2025

Historic Work In Process for Thermo Fisher Scientific (TMO) over the last 8 years, with Sep 2025 value amounting to $990.0 million.

  • Thermo Fisher Scientific's Work In Process was N/A to $990.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $990.0 million, marking a year-over-year change of. This contributed to the annual value of $755.0 million for FY2024, which is 7.09% up from last year.
  • As of Q3 2025, Thermo Fisher Scientific's Work In Process stood at $990.0 million, which was up 4.54% from $947.0 million recorded in Q2 2025.
  • Thermo Fisher Scientific's 5-year Work In Process high stood at $990.0 million for Q3 2025, and its period low was $705.0 million during Q4 2023.
  • Its 3-year average for Work In Process is $854.2 million, with a median of $874.0 million in 2025.
  • Data for Thermo Fisher Scientific's Work In Process shows a peak YoY rose of 7.09% (in 2024) over the last 5 years.
  • Over the past 3 years, Thermo Fisher Scientific's Work In Process (Quarterly) stood at $705.0 million in 2023, then grew by 7.09% to $755.0 million in 2024, then reached $990.0 million in 2025.
  • Its Work In Process was $990.0 million in Q3 2025, compared to $947.0 million in Q2 2025 and $874.0 million in Q1 2025.